Publication:
Health-related quality of life for pembrolizumab (pembro) plus ipilimumab (ipi) versus pembro plus placebo in patients with metastatic NSCLC with PD-L1 tumor proportion score >= 50%: KEYNOTE-598.

Simple item page
dc.contributor.authorsSendur, Mehmet Nahit; Reck, Martin; Rodriguez-Abreu, Delvys; Park, Keunchil; Lee, Dae Ho; Cicin, Irfan; Yumuk, Perran Fulden; Orlandi, Francisco J.; Leal, Ticiana A.; Molinier, Olivier; Soparattanapaisarn, Nopadol; Langleben, Adrian; Califano, Raffaele; Medgyasszay, Balazs; Hsia, Te-Chun; Otterson, Gregory Alan; Xu, Lu; Burke, Thomas A.; Samkari, Ayman; Boyer, Michael J.
dc.date.accessioned2022-03-10T18:03:16Z
dc.date.accessioned2026-01-11T06:43:14Z
dc.date.available2022-03-10T18:03:16Z
dc.date.issued2021
dc.identifier.doi10.1200/JCO.2021.39.15_suppl.9038
dc.identifier.eissn1527-7755
dc.identifier.issn0732-183X
dc.identifier.urihttps://hdl.handle.net/11424/222462
dc.identifier.wosWOS:000708120605019
dc.language.isoeng
dc.publisherLIPPINCOTT WILLIAMS & WILKINS
dc.relation.ispartofJOURNAL OF CLINICAL ONCOLOGY
dc.rightsinfo:eu-repo/semantics/closedAccess
dc.titleHealth-related quality of life for pembrolizumab (pembro) plus ipilimumab (ipi) versus pembro plus placebo in patients with metastatic NSCLC with PD-L1 tumor proportion score >= 50%: KEYNOTE-598.
dc.typeconferenceObject
dc.type.submeetingabstract
dspace.entity.typePublication
oaire.citation.issue15
oaire.citation.titleJOURNAL OF CLINICAL ONCOLOGY
oaire.citation.volume39

Files

Collections

Araştırma Çıktıları